Neal I Lindeman
Overview
Explore the profile of Neal I Lindeman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
6983
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forrest S, Gupta H, Ward A, Li Y, Doan D, Al-Ibraheemi A, et al.
Nat Commun
. 2024 Aug;
15(1):7218.
PMID: 39174503
No abstract available.
2.
Ghosh H, Patel R, Woodward E, Greenwald N, Bhave V, Maury E, et al.
Neuro Oncol
. 2024 Aug;
27(1):195-208.
PMID: 39164213
Background: With the significant shift in the classification, risk stratification, and standards of care for gliomas, we sought to understand how the overall survival of patients with these tumors is...
3.
Forrest S, Gupta H, Ward A, Li Y, Doan D, Al-Ibraheemi A, et al.
Nat Commun
. 2024 Jul;
15(1):5837.
PMID: 38992034
To inform clinical trial design and real-world precision pediatric oncology practice, we classified diagnoses, assessed the landscape of mutations, and identified genomic variants matching trials in a large unselected institutional...
4.
Christakis A, Nowak J, Hamilton M, Goldblum J, Parrack P, Lindeman N, et al.
J Clin Pathol
. 2024 Jun;
PMID: 38886044
Aims: Little is known about the molecular features of visible polyps with low-grade intestinal-type dysplasia in patients with inflammatory bowel disease (IBD). To better understand their origins and biological potential,...
5.
Furtado L, Bifulco C, Dolderer D, Hsiao S, Kipp B, Lindeman N, et al.
J Mol Diagn
. 2024 Jun;
26(8):653-668.
PMID: 38851389
Tumor mutational burden (TMB) has been recognized as a predictive biomarker for immunotherapy response in several tumor types. Several laboratories offer TMB testing, but there is significant variation in how...
6.
Zehir A, Nardi V, Konnick E, Lockwood C, Long T, Sidiropoulos N, et al.
Arch Pathol Lab Med
. 2023 Sep;
148(2):139-148.
PMID: 37776255
Context.—: The Sustainable Predictive Oncology Therapeutics and Diagnostics quality assurance pilot study (SPOT/Dx pilot) on molecular oncology next-generation sequencing (NGS) reportedly demonstrated performance limitations of NGS laboratory-developed tests, including discrepancies...
7.
AlJabban A, Paik H, Aster J, Berliner N, Brouillard J, Brown J, et al.
JCO Oncol Pract
. 2023 Sep;
20(2):220-227.
PMID: 37683132
Purpose: This study investigated the effectiveness of algorithmic testing in hematopathology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute (DFCI). The algorithm was predicated on test selection after...
8.
Pan E, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, et al.
Mol Cancer Ther
. 2023 Feb;
22(4):511-518.
PMID: 36780008
Given that radium-223 is a radiopharmaceutical that induces DNA damage, and olaparib is a PARP inhibitor that interferes with DNA repair mechanisms, we hypothesized their synergy in metastatic castration-resistant prostate...
9.
Lazo de la Vega L, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li Y, et al.
JCO Precis Oncol
. 2022 Nov;
6():e2200390.
PMID: 36446043
Purpose: Multiple FGFR inhibitors are currently in clinical trials enrolling adults with different solid tumors, while very few enroll pediatric patients. We determined the types and frequency of alterations ()...
10.
Fischer G, Lindeman N, Ligon A, Russell-Goldman E
Am J Dermatopathol
. 2022 Nov;
45(4):217-226.
PMID: 36346171
Proliferating pilar tumors (PPTs) are rare neoplasms of external root sheath derivation, which most commonly occur on the scalp of elderly women. Although typically showing classic histologic features such as...